Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2025

Revascularization vs. Optimal Medical Therapy of Chronic Total Occlusions for Symptom Relief and Quality of Life: From the EUROCTO and DECISION-CTO Randomized Trials

Presenter: Gerald S. Werner

October 25, 2025

News Conference News TCT 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Yael L. Maxwell

September 29, 2019

Presentation TCT 2018

Data Analysis: The Big Three Trials - Decision CTO, EURO CTO, OPEN CTO

Presenter: John A. Spertus, Robert W. Yeh, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2017

DECISION-CTO and EURO-CTO: Critique and Unanswered Questions

Presenter: David J. Cohen, Ajay J. Kirtane, Emmanouil S. Brilakis

November 01, 2017

Presentation TCT 2017

DECISION-CTO and EURO-CTO: Topline Findings and Practice Implications

Presenter: David J. Cohen, Ajay J. Kirtane, Gerald S. Werner

November 01, 2017

Presentation TCT 2017

Outcomes and Clinical Implications From DECISION-CTO

Presenter: Barry D. Rutherford, Robert W. Yeh, Seung-Whan Lee

October 31, 2017

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Todd Neale

October 31, 2017

Presentation TCT 2017

How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Laura Mauri

October 30, 2017

Presentation TCT 2016

Should Every CTO Be Opened? From the IRIS-CTO Registry to the Randomized (DECISION-CTO Trial)

Presenter: Seung-Jung Park, Alan C. Yeung, Seung-Whan Lee

October 31, 2016

Advertisement

Revascularization vs. Optimal Medical Therapy of Chronic Total Occlusions for Symptom Relief and Quality of Life: From the EUROCTO and DECISION-CTO Randomized Trials

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Data Analysis: The Big Three Trials - Decision CTO, EURO CTO, OPEN CTO

DECISION-CTO and EURO-CTO: Critique and Unanswered Questions

DECISION-CTO and EURO-CTO: Topline Findings and Practice Implications

Outcomes and Clinical Implications From DECISION-CTO

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others)

Should Every CTO Be Opened? From the IRIS-CTO Registry to the Randomized (DECISION-CTO Trial)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content